Bevacizumab, an antiangiogenic drug that targets VEGF ligands [10,11,12], has shown significant activity in GBM and is considered as a valid option by the Food Drug Administration (FDA) for the treatment of recurrent glioblastoma [12,13]. The gene discussed is VEGFA; the disease is glioblastoma.